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We appreciate Dr. Kaneda's astute observation about the data contained in our report (1) on the intravascular ultrasound (IVUS) results from TAXUS-IV. It is indeed true that there was a trend for the vessel receiving a TAXUS stent to demonstrate positive remodeling, similar to prior drug-eluting stent (DES) reports. The analysis for remodeling used only TAXUS and non-TAXUS patients with complete volumetric IVUS data of the external elastic membrane (EEM) throughout the stent length at both the time of stent implantation and at follow-up. As it states in the Methods section, "Volumes were calculated only if the vascular interface was visualized every millimeter throughout the stent" (i.e., we did not extrapolate the EEM border for images in which it was not visualized). Thus, not all patients with EEM volume data at stent implantation had EEM volume data at follow-up, and vice-versa. Table 2 of the study (1) reports all the volume data at one time point (postimplantation or follow-up) and the statistical analysis for change (and Figure 1 of 
Restenosis, Statistics, and Reasonable Inferences
We appreciate the accompanying editorial (1) to our recent report entitled "Relationship Between Angiographic Late Loss and Target Lesion Revascularization After Coronary Stent Implantation: Analysis From the TAXUS-IV Trial" (2) but we wish to clarify several apparent misconceptions. Our principal messages are that in the era of drug-eluting stents (DES), it is not only the mean value but also the shape of the distribution curve (variance and skewedness) that will determine the population target lesion revascularization (TLR), and that with a homogeneous response in-stent late losses up to about 0.75 mm may provide acceptable clinical results (2) . That DES may have rightward skewed late loss histograms has been previously reported (3) . The fact that the individual patient late loss/TLR relationship is curvilinear with an apparent inflection point, rather than linear, had not been reported and is a novel and unique observation that has since been replicated in several other DES trials (DELIVER, ENDEAVOR-II). Most importantly, given the rightward skew in patient population data seen in all these trials (including the pivotal SIRIUS trial of the sirolimus-eluting stent), a certain lower level or "floor" of TLR may be unavoidable, somewhat independent of the mean late loss. Moreover, recent data reported at the most recent American College of Cardiology meetings substantiate our findings. The ENDEAVOR-II trial, with a considerably higher mean late loss (0.62 mm) but with rather a homogeneous effect (standard deviation of late loss 0.46), reported a low TLR of 4.6% with the ABT-578-eluting stent. The large-scale REALITY trial, comparing the sirolimus-eluting and paclitaxel-eluting stents, found significantly greater in-stent late loss with the latter (0.09 vs. 0.31 mm, respectively, p Ͻ 0.001), but nearly identical eight-month TLR rates (5.0% vs. 5.4%, p ϭ 0.81). Thus, given the patient and lesion complexity studied in the pivotal DES trials to date, an "acceptable" TLR can be achieved with a relatively high in-stent late loss, providing that a homogeneous response is seen.
In addition, other variables beyond angiographic late loss that may affect TLR rates must be considered, including the inaccuracies and variability of quantitative measures of late loss. Variable thresholds of patient angina perception, follow-up ischemia detec-tion, and practice to refer patients for subsequent repeat catheter
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Although we appreciate the interest by Dr. Ellis and colleagues toward our recent editorial comment (1), we fear a central concept was missed. The argument that more late loss (as long as the absolute measure remains below some arbitrary threshold) is irrelevant as a measure of drug-eluting stent (DES) efficacy is both intuitively flawed and derived by an erroneous extrapolation from individual patient-level observations to mean late loss values. Across observed levels of mean late loss in recent trials, incremental changes in late loss are associated with increasing restenosis risk (2) . The relationship of mean late loss values to clinical restenosis does not follow the S-shaped curve presented by Dr. Ellis and colleagues but instead is curvilinear without an obvious inflection point (2) . Furthermore, results of randomized controlled clinical trials comparing the Cypher and Taxus stents for treatment of coronary stenoses in complex patient subsets do not support the "threshold" premise (3) (4) (5) (6) . Although the ISAR-DIABETES, SIRTAX, REALITY, and ISAR-DESIRE trials reported mean late loss values well below the 0.75 mm "threshold" for clinical significance set by Dr. Ellis and colleagues, the observed binary angiographic restenosis (BAR) and target lesion revascularization (TLR) rates were increased in proportion to increases in late loss (Table 1) . If coronary stents are deployed in one million individuals yearly, the relative percent differences in BAR and TLR observed in these trials translate into large socioeconomic differences (Ն50,000 more revascularization procedures yearly) and clearly support the premise that "less is better" with respect to late lumen loss in the DES era.
As we predicted in our editorial, when DES with apparent subtle differences in late lumen loss are compared, differences in late clinical/angiographic outcome measures are magnified in those patient cohorts with the greatest propensity for restenosis. Thus, late lumen loss remains a primary measure of stent efficacy, which correlates with late clinical/angiographic outcomes in the DES era. 
